anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To perform an extensive investigation of the clinical features and long-term complications among the n = 134 adults and children with nucleic acid amplification test (NAAT) verified SARS-CoV-2-infection in the immunologically naïve population of Ulvik, Norway, during the single variant B.1.1.7 outbreak in late January through February 2021.
METHODS: Every infected person regardless of whether symptoms of COVID-19 were present was invited to answer a web-based questionnaire at two- and seven months after testing positive. The period from initial infection to the first questionnaire was assessed retrospectively, and the time points at two- and seven months were assessed prospectively.
RESULTS: A total of 87 of 134 (65%) NAAT-positive persons answered the first questionnaire, of which 35/87 (40%) were children, and 74 of 87 (85%) answered the second questionnaire. Children experienced symptoms less often than adults during the acute phase of infection (51% (18/35) versus 81% (42/52) (p = .004)). At two-months follow-up 88% (53/60) of participants with symptoms during the acute phase, including all children, reported no longer having symptoms. Among those with persisting symptoms at seven months, fatigue (18/25) and insomnia (16/24) were common.
CONCLUSION: In an immunologically naïve population infected with the SARS-CoV-2 B.1.1.7 variant, the clinical features of acute phase symptoms were similar to previous studies. Children underwent asymptomatic infection more often than adults, and adults more often experienced persisting symptoms. Insomnia and fatigue were common complaints among those with persisting symptoms seven months after infection.
Contraceptive compns. for vaginal administration consist of a Na salt of sulfonated homo- or copolymers of styrene with a mol. wt. of 3,000-1,000,000 and a D.S. of 0.7-1.3 based on the sulfonyl gp. These compns. have a prolonged contraceptive physiol. effect and need not be inserted into the vagina prior to intercourse. Thus, a vaginal suppository is formulated from 91 polyethylene glycol 1000, 3 polyethylene glycol 300, 2 Me cellulose and 5 parts sulfonated polystyrene Na salt.  The polymer salts are tested in rabbits at 5, 25 and 50 mg/ml concns.  The percentage of pregnant rabbits is 20 at 50 mg/ml concn. of the polymo contraceptive.
Compositions and methods for improving cellular internalization of one or more compounds are disclosed. The invention provides a drug conjugate composition that can be delivered to a target cell, which comprises a carrier compound that has a binding specificity for a receptor molecule and is conjugated to a therapeutic or diagnostic moiety. When this composition is administered to a subject, the carrier compound binds to the receptor and is internalized by the target cell. Furthermore, monoclonal antibodies are disclosed that are internalized into target cells. The monoclonal antibodies of the invention are specific for target cells, particularly for cells expressing the surface antigen p185HER-2. The antibodies of the invention may be conjugated with a molecule for delivery into a target cell. Such molecules may be used for therapeutic treatment, including gene therapy, and for imaging. The invention also provides DNA sequences of the variable regions of particular monoclonal antibodies.
A method for enhancing immunogenicity of an epitope peptide of an HPV antigen, the method including: assembling a gene of an HPV antigen into a gene of HBc, exogenously expressing a resulting assembled gene to acquire a fusion protein, allowing the fusion protein to automatically assemble to form a virus-like particle including the HPV antigen on a surface of the virus-like particle, to obtain HBc-HPV virus-like particle. A virus-like particle capable of expressing the antigen peptide of HPV acquired by the method. The virus-like particle includes a HBc-L2 fusion protein. A genome for encoding the HBc-L2 fusion protein is represented by SEQ ID NO. 3. A method for preparing an HPV vaccine includes using the virus-like particle.
Bacterial superinfection represents a major treat for patients admitted to intensive care unit (ICU), severely impacting clinical outcome and length of hospital stay. Several studies showed that previous multidrug-resistant organisms (MDRO) colonization is a major risk factor for subsequent infection. The coronavirus disease 2019 (COVID-19) pandemic caused an unprecedented rate of ICU admissions and drastically changed the ICU care itself, in terms of infection control measures and therapeutic usage of immunomodulating drugs. Depending on the study, incidence of bacterial infections acquired in COVID-19 ICUs ranges from 12% to 50%. In a retrospective, multicenter study conducted in 8 Italian ICUs during the first wave of the pandemic (March 2020-May 2020), 46% of the patients developed a bacterial superinfection. Notably, 35% of these infections were caused by MDRO. To date there is still scarce evidence on the incidence of colonization by MDRO in patients admitted to COVID-19 ICUs, and little data has been collected on risk factors associated with MDRO colonization. Based on case series analysis, MDRO colonization has been associated with presence of invasive devices, prolonged ICU stay and use of corticosteroids and antibiotics.

The Milano Fiera ICU was a large, modular, COVID-19 ICU built in Milan, Italy, in March 2020 to face the impact of the pandemic. It was composed of distinct units (modules) to accommodate up to 100 patients with severe SARS-CoV-2 infection requiring mechanical ventilation. Since October 2020, over 400 mechanically ventilated COVID-19 patients were admitted to Milano Fiera ICU. Despite each module was managed by staff coming from different hospitals in the Milan area, microbiological surveillance was standardized, and all modules referred to the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan for laboratory analysis and infectious disease specialist consultation.

The present retrospective single-center cohort study aims to evaluate the incidence of colonization by MDRO in patients admitted to the Milano Fiera ICU during the second wave of COVID-19 pandemic (October 2020-May 2021). Furthermore, the study will evaluate the overall incidence of infections during the ICU stay and analyze the risk factors associated with bacterial superinfection and with MDRO colonization.
Dietary supplements are commonly used during conventional cancer treatment. Vitamin E has a variety of functions, including enhancing immunity, anti-inflammation, and anti-oxidation. Tislelizumab is an anti-PD-1 monoclonal antibody, and furoquininib is a tyrosine kinase inhibitor that inhibits tumor angiogenesis. Studies have shown that immunotherapy combined with furoquininib has initial efficacy in the treatment of colorectal cancer. Whether vitamin E combined with immunotherapy and furoquininib can improve the prognosis of patients with colorectal cancer deserves to be studied. Therefore, the objective of this study is to evaluate the efficacy and safety of Vitamin E in combination with Fuquinitinib and Tirelizumab in patients with microsatellite stabilized mCRC who have failed standard therapy.
Pre-existing depression may emerge or worsen during use of benzodiazepines including lorazepam. Lorazepam is not recommended for use in patients with a primary depressive disorder or psychosis.

Use of benzodiazepines, including lorazepam, both used alone and in combination with other CNS depressants, may lead to potentially fatal respiratory depression. (See ). PRECAUTIONS, Clinically Significant Drug Interactions

Use of benzodiazepines, including lorazepam, may lead to physical and psychological dependence.

As with all patients on CNS-depressant drugs, patients receiving lorazepam should be warned not to operate dangerous machinery or motor vehicles and that their tolerance for alcohol and other CNS depressants will be diminished.

Physical And Psychological Dependence

The use of benzodiazepines, including lorazepam, may lead to physical and psychological dependence. The risk of dependence increases with higher doses and longer term use and is further increased in patients with a history of alcoholism or drug abuse or in patients with significant personality disorders. The dependence potential is reduced when lorazepam is used at the appropriate dose for short-term treatment. Addiction-prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving lorazepam or other psychotropic agents.

In general, benzodiazepines should be prescribed for short periods only (e.g. 2 to 4 weeks). Extension of the treatment period should not take place without reevaluation of the need for continued therapy. Continuous long-term use of product is not recommended. Withdrawal symptoms (e.g. rebound insomnia) can appear following cessation of recommended doses after as little as one week of therapy. Abrupt discontinuation of product should be avoided and a gradual dosage-tapering schedule followed after extended therapy.

Abrupt termination of treatment may be accompanied by withdrawal symptoms. Symptoms reported following discontinuation of benzodiazepines include headache, anxiety, tension, depression, insomnia, restlessness, confusion, irritability, sweating, rebound phenomena, dysphoria, dizziness, derealization, depersonalization, hyperacusis, numbness/tingling of extremities, hypersensitivity to light, noise, and physical contact/perceptual changes, involuntary movements, nausea, vomiting, diarrhea, loss of appetite, hallucinations/delirium, convulsions/seizures, tremor, abdominal cramps, myalgia, agitation, palpitations, tachycardia, panic attacks, vertigo, hyperreflexia, short-term memory loss, and hyperthermia. Convulsions/seizures may be more common in patients with preexisting seizure disorders or who are taking other drugs that lower the convulsive threshold such as antidepressants.

There is evidence that tolerance develops to the sedative effects of benzodiazepines.

Lorazepam may have abuse potential, especially in patients with a history of drug and/or alcohol abuse.
A guest engagement system and associated methods provide seamless engagement with guests of facilities through the use of wireless sensing technologies. The system makes use of individual guest devices which are carried by guests and used to automatically identify and authenticate the guests throughout the facility. Services can thereby be seamlessly provided to the guests throughout the facility. The services include contact tracing, automatic unlocking of doors, including hotel or state room doors, based on the guests’ immediate proximity to their assigned room’s door. The services also include automated payment services provided at checkout or vending terminals, and automated log-on to interactive displays and portals, among others, based on secure wireless authentication of the guest devices. The guest devices can each include a device health sensor configured for measuring at least one health function of a user wearing the guest device.
BACKGROUND: Sarcopenia is common in patients with cirrhosis and is a risk factor for increased mortality. Transjugular intrahepatic portosystemic shunt (TIPS) placement has been utilized in cirrhosis patients with decompensation . We investigated the role of sarcopenia in predicting mortality in patients undergoing TIPS.
METHODS: We conducted a single-center retrospective study of 232 patients with cirrhosis who underwent TIPS between January 2010 and December 2015. Sarcopenia was defined by the psoas muscle index (PMI) cutoff value, calculated based on dynamic time-dependent outcomes using X-tile software. Kaplan-Meier analysis demonstrated the difference in survival in the sarcopenia group versus the non-sarcopenia group. . Univariate and multivariate analyses were used to identify the relationship between sarcopenia and post-TIPS mortality during a follow-up period of 1 year.
RESULTS: For TIPS indications, 111 (47.84%) patients had refractory ascites, 69 (29.74%) patients had variceal bleeding, 12 (5.17%) patients had ascites, and 40 (17.24%) for other indications. The mean PMI was 4.40 ± 1.55. Sarcopenia was defined as a PMI value of <4.36 in males, and <3.23 in females. Sarcopenia was present in 96 (41.38%) of patients. . Kaplan-Meier analysis showed thatsarcopenia is associated with worse survival (log-rank P  < 0.01). Multivariate Cox regression analysis showed that sarcopenia is independently associated with worse survival during the 1-year follow-up period with an hazard ratio of 2.435 (95% CI 1.346-4.403) ( P  < 0.01), after adjusting for age, BMI, indications for TIPS, etiology for cirrhosis, and MELD score and stratified by sex.
CONCLUSION: Sarcopenia is an independent risk factor for 1-year mortality in patients undergoing TIPS and should be considered when patients are evaluated as a candidate for TIPS.
FIELD: cosmetics, pharmacy technology. SUBSTANCE: base is prepared by dispersing vegetable oil, glycerol and emulsifier in dispersion medium followed by addition of biologically active substances of plant origin to obtained emulsion in the process of its stirring. Polyethylene oxide gel is used as an emulsifier. Also, biologically active substances of animal origin are added additionally to obtained emulsion during stirring. Components of an agent are dispersed at the room temperature. An agent is prepared at the following quantitative ratio of components, wt.-%: vegetable oil 1.0-25.0; glycerol in combination of biologically active substances of animal origin 2.0-27.5; biologically active substances of plant origin 1.0-5.0, and polyethylene oxide gel - the rest. An agent is used for face skin, head and hair care. EFFECT: increased stability of an emulsion, enhanced effectiveness, decreased energy consumption. 3 cl, 4 ex
A horse shoe 1 has a sole member 2 , a front panel 5 which is connected to and extends upwardly from the front of said sole 2 so as, in use, to extend along the front of the hoof of an animal, and a back panel 8 which is connected to and extends upwards from the back of said sole 2 so, in use, to extend along the back of the hoof of an animal. A front strap assembly is composed of a pair of front securing swaps 21b, 24, a first 21b of which extends around the bottom of the shoe proximate to the back thereof from one side of the shoe to the other, and a second 24 of which extends obliquely from one side of the shoe, around the front panel 5 proximate to an ankle opening therein, to the other side. A rear strap assembly is composed of a pair of rear securing straps 22b, 26, a first 22b of which extends around the bottom of the shoe proximate to the front thereof from one side of the shoe to the other, and a second 26 of which extends obliquely from one side of the shoe around the back 8 of the shoe proximate to the ankle opening, to the other side. The first and second front swaps are connectable to each other and the first and second rear straps connectable together so as to secure the shoe on the animal hoof. A medical composition, is also defined comprising 95% to 99% Glycerine, 3 to 8 g/kg of Lavendula angustfolia x latifolia, 0.5 to 1.5 g/kg Arnica Montana and 1.5 to 10 g/kg Melaleuca alternifolia for use as a medicament. A paste may be applied to the hoof by use of the shoe. In a medical shoe, the inner sole may be replaced by a gauze pad to treat a foot injury, or such a gauze may be formed separately from and be insertable into the shoe.
Participants in the guided mindfulness study arm will be lead through a seated mindfulness exercise. This intervention exercise will be completed daily for a period of 8 weeks.
FIELD: medicine.SUBSTANCE: invention refers to therapy and hepatology, and can be used for treating non-alcoholic fatty liver disease accompanying metabolic syndrome. That is ensured by administering ursodeoxycholic kilo in dose of 15 mg/kg for 6 months if the transaminase level is more than three. Additionally, diet therapy is performed within 12 months with restriction of fats and usage of carbohydrate-containing products with glycemic index less than 70, at that reducing caloric content of ration by 500 kcal from initial one. Minimum calorie intake per day shall be not less than 1,200 kcal for women and not less than 1,500 kcal for men. Additionally, the HOMA-IR insulin resistance index is calculated. If HOMA-IR is more than 2.7 Glucophage® Long 1,000 mg is prescribed in the evening after lunch for 12 months. That is followed by determining ferritin level in blood serum. If the ferritin value is 60 mcg/l and higher, Thiogam 600 mg is prescribed for 3 months, then in dose of 300 mg for following 3 months.EFFECT: method provides reduced hepatic steatosis, reduced degree of abdominal obesity and metabolic disorders ensured by the hepatoprotective effect of the therapy, higher tissue sensitivity to insulin, reduced transaminase ACT, ALT and lipids, namely total cholesterol, low-density lipoprotein cholesterol and triglycerides.1 cl, 3 tbl, 1 ex
Ocular inflammatory diseases, including uveitis, cause significant visual loss. Previous non-human investigations have identified several cell types, receptor systems and metabolic intermediates that have led to treatment approaches for human patients. However, information on the human genetic expression of these steps in defined inflammatory disease states is lacking. This non-intervention study proposes to obtain peripheral blood and tissue specimens from patients enrolled in other intramural trials for ocular inflammatory diseases and to apply contemporary cDNA microarray technologies for the analysis of differential gene expression. Test results will not be reported to participants or used for diagnostic or therapeutic purposes.

The study's primary objective is to identify unique gene expression profiles as well as disease relevant genes for patients with ocular inflammatory disease at defined clinical stages using cDNA microarray analysis. This will help provide further insight to understand the pathological mechanisms and potential targets for treatment. Some 3,000-5,000 genes will be examined starting with a selected set associated with interleukin (IL) proteins and their receptors, and with tumor necrosis factors (TNF). Purified peripheral blood mononuclear cells (or whole blood lysates using RNA isolation procedures) will be used to isolate total RNA from these samples. Samples will be taken during periods of active or recurring inflammatory disease and again during periods of quiescence after treatment. The microarray tools and methods for genetic analysis are now available both at NEI and the collaborating NIA laboratories.

A secondary objective is to analyze the circulating protein profiles in serum or other available tissue or fluid specimens from patients with ocular inflammatory disease at the same time points as described above. These samples will be analyzed using 2-dimensional SDS-PAGE for profiling proteomic differences in patients at defined clinical stages. In-gel digestion and subsequent sequence analysis by mass spectroscopy will be performed if differentially expressed protein(s) of interest are to be identified. Other methods such as flow cytometry analysis and proliferation assays using purified PBMCs will be used to examine expression status of cell surface markers of interest (e.g., CD25) as well as responses to antigen and mitogens at the peak and trough serum concentrations of daclizumab therapy.
PURPOSE:To provide an immuno-activating agent containing actinonin or its salt as an active component. CONSTITUTION:An immuno-activating agent can be prepared by using actinonin of formula or its salt as an active component. The compound of formula is present in the culture liquid of an actinonin-producing microbial strain MG848-hF6, and can be separated in high yield by the adsorption and desorption of the filtrate of the culture liquid using an adsorbent. It can be administered in the form of oral drug, injection or rectal suppository. The active component may be added with a pH-modifier, a buffering agent, a stabilizer, an isotonic agent, a local anesthetic, etc. to obtain an injection for subcutaneous, intramuscular or intravenous injection. The solid preparation of the objective compound for oral administration is tablet, granule, capsule, etc. The drug can be administered also in the form of syrup, suppository, etc. Dose: 1-200mg/dose and 1 dose per day. It can be used in combination with other immuno-activating agent.
Other adverse experiences that have been reported with hydrochlorothiazide, without regard to causality, are listed below:

Body as a Whole: weakness; Digestive: pancreatitis, jaundice (intrahepatic cholestatic jaundice), sialadenitis, cramping, gastric irritation; Hematologic: aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia; Hypersensitivity: purpura, photosensitivity, urticaria, necrotizing angiitis (vasculitis and cutaneous vasculitis), fever, respiratory distress including pneumonitis and pulmonary edema; Metabolic: hyperglycemia, glycosuria, hyperuricemia; Musculoskeletal:  muscle spasm; Nervous System/Psychiatric:  restlessness; Renal: renal failure, renal dysfunction, interstitial nephritis; Skin:  erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis; Special Senses: transient blurred vision, xanthopsia.

Persistent dry cough (with an incidence of a few percent) has been associated with ACE-inhibitor use and in practice can be a cause of discontinuation of ACE-inhibitor therapy. Two prospective, parallel-group, double-blind, randomized, controlled trials were conducted to assess the effects of losartan on the incidence of cough in hypertensive patients who had experienced cough while receiving ACE-inhibitor therapy. Patients who had typical ACE-inhibitor cough when challenged with lisinopril, whose cough disappeared on placebo, were randomized to losartan 50 mg, lisinopril 20 mg, or either placebo (one study, n=97) or 25 mg hydrochlorothiazide (n=135). The double-blind treatment period lasted up to 8 weeks. The incidence of cough is shown below.

These studies demonstrate that the incidence of cough associated with losartan therapy, in a population that all had cough associated with ACE-inhibitor therapy, is similar to that associated with hydrochlorothiazide or placebo therapy.

Cases of cough, including positive re-challenges, have been reported with the use of losartan in post-marketing experience.
Recent findings have shown that the level of interleukin-35 (IL-35) is abnormal in several autoimmune diseases. Nonetheless, whether IL-35 participates in the pathogenesis of immune thrombocytopenia (ITP) remains unclear. The current study investigates whether IL-35 modulates megakaryopoiesis. The results show that IL-35 receptors are progressively expressed on bone marrow megakaryocytes during the in vitro differentiation of CD34+ progenitors. IL-35 increases the number of megakaryocyte colony-forming units through the Akt pathway. The level of bone marrow IL-35 is reduced in ITP patients, and the decreased level of IL-35 may inhibit megakaryopoiesis. Then, the potential causes of decreased IL-35 in ITP patients are explored. The primary type of cell that secretes IL-35, known as IL-35-producing regulatory T cells (iTr35), is reduced in ITP patients. Bone marrow mesenchymal stem cells (MSCs) from ITP patients exhibit an impaired capability of inducing iTr35 due to enhanced apoptosis, which may contribute to the reduced level of bone marrow IL-35 in ITP patients. Iguratimod promotes megakaryocyte development and differentiation by elevating the expression of IL-35 receptors on megakaryocytes. Iguratimod improves response rates and reduces bleeding symptoms in corticosteroid-resistant ITP patients.